

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1704323> since 2019-08-05T11:47:01Z

Published version:

DOI:10.23736/S0026-4806.19.06108-1

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study

Journal: Minerva Medica

Paper code: Minerva Med-6108

Submission date: April 16, 2019

Article type: Original Article

Files:

1. Manuscript

Version: 2

Description: Rosso_Manuscript

File format: application/msword

2. Figures 1

Version: 1

Description: Rosso_Figure 1

File format: application/pdf

3. Figures 2

Version: 1

Description: Rosso_Figure 2

File format: application/pdf

4. Supplementary Digital Material 1

Version: 1

Description: Rosso_Supplementary Material

File format: application/msword

1 **Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a**
2
3 **single center retrospective study**
4

5
6
7 ¹Chiara Rosso, ¹Gian Paolo Caviglia, ¹Michela Ciruolo, ¹Alessia Ciancio, ¹Ramy Younes,
8
9 ¹Antonella Olivero, ²Chiara Giordanino, ¹Giulia Troshina, ¹Maria Lorena Abate, ¹Mario Rizzetto,
10
11 ²Rinaldo Pellicano, ¹Giorgio Maria Saracco, ¹Elisabetta Bugianesi, ¹Antonina Smedile
12
13

14
15
16 ¹Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy
17

18 ²Department of Gastro-Hepatology, Città della Salute e della Scienza University Hospital, Turin,
19
20 Italy.
21

22
23
24
25 Corresponding author: Chiara Rosso

26
27 Division of Gastroenterology

28
29 Department of Medical Sciences

30
31 University of Turin, Turin, Italy

32
33 e-mail: chiara.rosso@unito.it
34
35
36
37
38
39

40 **Key words:** Hepatitis C Virus, Long Term Responders, metabolic cofactors, steatosis
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Summary

Background. Obesity, type 2 diabetes (T2D), dyslipidemia, arterial hypertension as well as hepatic steatosis (HS) are common conditions that can affect clinical outcomes of patients with chronic hepatitis C (CHC) who achieved sustained virological response (SVR). The aim of this study was to assess the impact of metabolic cofactors on the occurrence of clinical events during follow-up (FU) in a group of CHC long term responders (LTRs) to interferon (IFN) -based therapy.

Methods. A total of 5172 medical records of CHC patients enrolled from 1990 to 2011 were examined. 1034/5172 (20%) patients were treated with IFN-based therapy and 382/1034 (37%) of them achieved SVR. A total of 188 (49%) LTRs performed liver biopsy before antiviral treatment. Data on liver and cardiometabolic events such as cirrhosis and its complications, hepatocellular carcinoma, coronary artery disease, arterial hypertension, impaired fasting glucose (IFG)/type 2 diabetes (T2D) and dyslipidemia, were collected over time.

Results. The mean age of the whole cohort was 46 ± 12 years and 114/188 (61%) patients were males. HS was found in 82/188 (43.6%) patients and most of them were infected by HCV genotype 3a. The prevalence of obesity, IFG/T2D, dyslipidemia and arterial hypertension was 4.3%, 6.9%, 37.2% and 5.9%, and was similarly distributed among patients with and without HS. Cirrhosis was histologically diagnosed in 18/188 (9.6%) patients. After a median follow-up of 11 years (range 3-21), the cumulative incidence of cardiovascular events, IFG/T2D and dyslipidemia was higher in CHC-LTRs who had HS at baseline compared to those without HS (1.2%, 2.3% and 3.0% vs 0.4%; 0.8% and 2.5%, respectively). At multivariable Cox regression analysis, HS was significantly associated to the development of cardiovascular events and IFG/T2D (HR=5.2, 95%CI=1.3-20.7, p=0.019 and HR=2.6, 95%CI=1.1-6.2, p=0.027, respectively).

Conclusions. In CHC-LTRs, HS at baseline may predispose to the development of cardiovascular events and T2D during follow-up emphasizing the importance of an accurate counseling in order to prevent extra-hepatic complications.

Introduction

For nearly 30 years, interferon (IFN) alone or in combination with ribavirin (RBV), has been the gold standard for the treatment of hepatitis C virus (HCV) infection. The rate of treatment success is closely linked to viral and host factors such as HCV-genotype, patient age, sex, genetic factors, stage of liver fibrosis and the presence of other comorbidities.¹⁻² Sustained virological response (SVR), defined as undetectable HCV-RNA 24 weeks after the end of therapy, was achievable in 75% of patients infected with genotypes 2 and 3 and only in 40–50% of patients infected with genotype 1.³⁻⁵ It is well known that viral eradication improves liver histology, quality of life and reduces the risk to develop cirrhosis and hepatocellular carcinoma (HCC).⁶⁻⁷ Metabolic cofactors such as obesity, insulin resistance (IR), type 2 diabetes (T2D) and dyslipidemia may impact on the morbidity and mortality of chronic hepatitis C (CHC) accelerating the progression of liver fibrosis, increasing the risk of developing HCC and reducing the response to antiviral therapy.⁸⁻⁹ From a metabolic point of view, HCV infection resembles non-alcoholic steatohepatitis (NASH) for the impairment of glucose metabolism even if the signaling pathways involved are different. The prevalence of hepatic steatosis (HS) in the setting of CHC is around 40%¹⁰ while the risk to develop T2D is higher compared to the other chronic liver diseases suggesting a potential diabetogenic effect of the virus.¹⁰ Specifically, HCV core protein impairs insulin pathway increasing the phosphorylation of insulin receptor substrate-1 (IRS-1) through the up-regulation of the suppressor of cytokine signaling (SOCS) that in turn impairs insulin signaling. In HCV genotype 3 patients, the up-regulation of SOCS leads to a down-regulation of the peroxisome proliferator-activated receptor-g (PPARg) promoting HS thus IR.¹¹⁻¹² Conversely, in patients with non-3 HCV genotypes, HS is associated with body mass index (BMI) and IR and may persist even if the viral infection is resolved.^{10,13}

1 Similarly, HCV can affect lipid metabolism through its interaction with very low density
2 lipoproteins (VLDL) and low density lipoproteins (LDL). The association of HCV with host
3 lipoproteins facilitates its entry into the hepatocytes favoring the development of chronic liver
4 disease.¹⁴ The association between HCV infection and metabolic alterations may predispose to the
5 development of clinical events over time notwithstanding viral eradication, accelerating liver
6 fibrosis. In CHC patients who achieved SVR after IFN+RBV therapy, the assessment of metabolic
7 derangement is crucial for their management to prevent the occurrence of hepatic and cardio-
8 metabolic events over time. Furthermore, this strategy remains important also in the era of the new
9 drugs named direct antiviral agents (DAAs) characterized by a high HCV eradication rate.¹⁵ In this
10 context, the aim of this study was to define the main baseline metabolic predictors of clinical
11 outcomes in a monocentric cohort of CHC-LTRs who underwent liver biopsy at the time of HCV
12 antiviral therapy.

29 **Materials and Methods**

31 *Patients*

32 From 1990 to 2011, a total of 5172 patients were approached at the Division of Gastroenterology
33 and Hepatology, Città della Salute e della Scienza University Hospital, Turin. All the available
34 medical records were retrospectively examined. Patients included in the study were infected with
35 HCV, underwent IFN-based therapy (IFN mono-therapy or pegylated IFN plus RBV) and achieved
36 a SVR (Figure 1). Patients with HCV/HBV coinfection (N=12), with a follow-up period less than 3
37 years (N=35) and without liver biopsy prior to treatment (N=147) were excluded from the analysis
38 (Figure 1).

39 Antiviral therapy duration was 48 weeks or less according to specific guidelines.⁵ The beginning of
40 follow-up for each patient started at the initiation of antiviral therapy while the end coincided with
41 the last medical examination available (at least three years after the end of treatment). Long-term
42

1 response was defined as the maintenance of SVR throughout follow-up which had an average of 10
2 years (range 3-21 years). Liver enzymes (AST, ALT, GGT) and metabolic parameters (total-
3 cholesterol, triglycerides, glucose), BMI and instrumental examination (abdominal ultrasound [US])
4 were collected from medical records prior to treatment initiation and at the last available follow-up
5 visit. Liver biopsies were analyzed at baseline by an expert pathologist. Hepatic fibrosis and
6 inflammation were scored according to Ishak classification.¹⁶ Steatosis was defined as absent or
7 significant if the percentage of fat into the hepatocytes was less than 5% or $\geq 5\%$, respectively.
8 All patients gave their consent for including their personal data in the database. The study was
9 approved by the ethics committee of the University Hospital Città della Salute e della Scienza of
10 Turin and was in accordance with the Helsinki Declaration.

24 ***Metabolic cofactors definition***

25 Metabolic cofactors considered in this study were: overweight/obesity (BMI ≥ 24.9 kg/m²/BMI \geq
26 29.9 kg/m²), impaired fasting glucose (IFG)/T2D (fasting glucose levels ≥ 110 mg/dl), dyslipidemia
27 (total cholesterol ≥ 200 mg/dl, triglycerides ≥ 150 mg/dl), arterial hypertension ($\geq 130/85$ mm/Hg)
28 and HS at biopsy ($\geq 5\%$).

37 ***Follow up and clinical outcomes***

38 All the patients were followed-up for at least 3 years (median FU period 10 years): every 6 months
39 after the end of antiviral treatment for the first 2 years and every 24 months, subsequently. Cirrhotic
40 patients were examined every 6 months. The liver-related events occurred during FU and
41 considered for the analysis were collected from the outpatients' registries and were: the
42 development of cirrhosis and its complications (ascites, bleeding varices, hepatic encephalopathy
43 and HCC). The diagnosis of HCC was done using imaging techniques. The cardiovascular events
44 considered in the analysis included acute myocardial infarction and stroke.

Statistical analysis

Data are reported as mean and standard deviation (SD) for continuous normally distributed variables, as median and interquartile range (25^o-75^o percentiles) for continuous non-normally distributed variables and as number and frequency (%) for categorical variables. Data normality was checked by D'Agostino-Pearson test. Comparisons between groups were performed using the two-tailed Student's t-test, for normal continuous variables, and the Kruskal-Wallis non-parametric test, for non-normal continuous variables. For categorical data, the Fisher exact test or the Chi-square test were used as appropriate. To assess the occurrence of liver/cardio-metabolic events over time, according to the presence of baseline metabolic cofactors, the Kaplan-Meier survival analysis was performed and differences between the curves were determined by the Logrank test. To evaluate the risk to develop clinical events in the FU, univariate and multivariable Cox regression analysis adjusted for age, sex and BMI were performed. All the analysis were performed with MedCalc software version 12.7.

Results

Clinical features of the study population at baseline

A total of 188 CHC patients (114 male, 61%) were followed-up for 3 to 21 years (mean 11 years). Most of the patients (93%) were treated with the combination of pegylated IFN and RBV while the others received the IFN monotherapy. Baseline clinical, biochemical and histological characteristics of the study cohort, according to the presence or absence of HS, are reported in Table 1. HS was found at liver biopsy in 82 CHC patients with a prevalence of 43.6%. Patients with HS were older and showed a higher BMI compared to those without HS. Overall, 33 patients (17.6%) were infected by HCV genotype 3a and most of them (22 out of 33, 67%) had HS. Overall, the prevalence of obesity, IFG/T2D, dyslipidemia and arterial hypertension was 4.3%, 6.9%, 37.2% and

1 5.9%, respectively, and was not different in the two groups. Older age, HCV genotype 3a, and
2
3 dyslipidemia were significantly associated to the presence of baseline HS at univariate logistic
4
5 regression analysis but, after multivariable regression analysis, the only factor significantly
6
7 associated to HS was HCV-genotype 3a (odds ratio [OR]=8.4; 95% confidence interval [CI] 2.7-
8
9 26.0, $p<0.001$) (Supplementary Table 1).

14 ***Follow-up analysis***

15
16 After 20 years of follow-up, one CHC patient had a recurrence of HCV infection. Of the 6 deaths
17
18 occurred, 2 LTRs died for liver-related events, 3 for cardiovascular events and 1 for colorectal
19
20 cancer (Table 2). The cumulative incidence of mortality was similar in LTRs who had HS at biopsy
21
22 compared to those who did not have HS (Table 2).

27 ***Liver-related morbidity***

28
29 Liver-related events occurred in 5 LTRs with a cumulative incidence of 0.3%. One subject
30
31 developed cirrhosis, 1 with pre-existent cirrhosis at baseline developed its complications (hepatic
32
33 decompensation), 3 subjects developed HCC (2 on cirrhotic liver and 1 on non-cirrhotic liver with
34
35 steatosis). Baseline HS did not impact on the development of liver-related events during follow-up
36
37 (Table 2). Conversely, CHC-LTRs who had severe fibrosis at baseline showed a higher cumulative
38
39 incidence of liver related outcomes compared to those with mild/moderate fibrosis (0.9% vs 0.1%,
40
41 $p<0.001$) (Supplementary Table 2). After multivariable Cox regression analysis adjusted for age,
42
43 sex, BMI and HCV genotypes, severe fibrosis was the only baseline predictor of liver-related
44
45 outcomes with a hazard ratio (HR) of 11 (95% CI=1.5-87.9, $p=0.025$, data not shown).
46
47
48
49

51 ***Cardiometabolic-related morbidity***

1 Overall, cardiovascular events occurred in 14 LTRs and the cumulative incidence was significantly
2 higher in those who had HS at liver biopsy compared to those without HS (1.2% vs 0.4%, $p=0.011$)
3 (Table 2). At univariate Cox regression analysis, IFG/T2D, dyslipidemia and HS showed a higher
4 probability to develop cardiovascular events (Figure 2 A-C). After multivariable Cox regression
5 analysis, the only metabolic cofactor significantly associated to a higher risk of developing
6 cardiovascular events was IFG/T2D (HR=5.2, 95% CI=1.3-20.7, $p=0.019$) (Table 3).

7 Arterial hypertension occurred in 24 LTRs with a similar cumulative incidence in both patients with
8 and without HS at liver biopsy (1.4% vs 1.3%, $p=0.610$) (Figure 2D). At univariate Cox regression
9 analysis, no metabolic cofactors were significantly associated to the development of arterial
10 hypertension over time, and multivariable analysis confirmed this result.

11 Overall, the cumulative incidence of overweight/obesity, IFG/T2D and dyslipidemia was 1.2%,
12 1.5% and 2.8%, respectively (Table 2). Specifically, the cumulative incidence of IFG/T2D and
13 dyslipidemia was significantly higher in LTRs who had HS at liver biopsy compared to those who
14 did not have HS (2.3% vs 0.8%, $p=0.005$ and 3.0% vs 2.5%, $p=0.010$, respectively), while the
15 cumulative incidence of overweight/obesity was similar among the two groups.

16 At univariate Cox regression analysis, older age, dyslipidemia and HS were significantly associated
17 to the development of IFG/T2D. After multivariable analysis, the only baseline metabolic cofactor
18 associated to the development of IFG/T2D was HS (HR=2.6, 95% CI=1.1-6.2, $p=0.027$) (Table 4).
19 Concerning the other metabolic outcomes, older age increased the risk of developing dyslipidemia
20 during follow-up (HR=1.0, 95% CI=1.0-1.1, $p=0.005$) (Supplementary Table 3) while no baseline
21 cofactors increased the risk of overweight/obesity over time.

22 Discussion

23 In this study, on 188 CHC LTRs to IFN and RBV therapy, we assessed the impact of metabolic
24 cofactors (HS, overweight/obesity, T2D, dyslipidemia and arterial hypertension) on the
25

1 development of clinical events (both hepatic and cardio-metabolic) during a long follow-up.
2
3 Particularly, it is well known that HS may be considered as a marker of metabolic dysfunction
4
5 predisposing to the development of clinical events even after a long time from HCV eradication. On
6
7 the other side, CHC infection has been associated with a poor prognosis affecting both liver- and
8
9 cardio-metabolic-related outcomes.¹⁷

10
11 The median duration of FU was 11 years (range 3-21), one of the longer. Concerning virological
12
13 and histological characteristics, our population slightly differs from another cohort of 150 Italian
14
15 CHC-LTRs. In fact, in the former, the prevalence of HCV genotype 3a was higher compared to that
16
17 reported by Morisco (17.6% vs 3.3%). Similarly the prevalence of cirrhosis was higher in our
18
19 cohort compared to that reported in the other cohort (9.6% vs 1.3%).¹⁸

20
21 At the time of baseline screening for antiviral therapy, HS was found at liver biopsy in 82 LTRs
22
23 with a prevalence of 43.6%. This data was in agreement with several studies indicating that, in the
24
25 setting of HCV infection, the prevalence of HS may range from 42% to 73%.¹⁹⁻²⁰ It is well known
26
27 that HS can be induced directly by HCV genotype 3a (viral steatosis) or indirectly, through the
28
29 development of IR, by HCV-genotype 1 (metabolic steatosis).²¹⁻²⁶ Particularly, HCV genotypes 1
30
31 and 4 infection is associated to the development of IR regardless of the presence of steatosis.^{23, 27-28}

32
33 Recently, Lerat et al. demonstrated that in HCV transgenic mice, the development of IR and glucose
34
35 intolerance are supported by HCV *per se* through the expression of viral proteins in the hepatocytes
36
37 which negatively act on the glucose uptake by the liver through the down-regulation of Glut2 and
38
39 IRS-2 expression via SOCS3-dependent mechanisms.²⁸ Unfortunately, in our population we did not
40
41 have data on homeostasis model of assessment (HOMA)-IR, but we showed that in HCV patients
42
43 infected with HCV genotype non-3, baseline BMI was significantly higher compared to those
44
45 infected with HCV genotype 3a indicating that in the first group, steatosis was mainly driven by
46
47 metabolic rather than viral derangements. Conversely, 67% of HCV genotype 3a infected patients
48
49 had HS at biopsy, probably driven by viral infection.
50
51
52
53
54
55

1 Overall, our population of LTRs had a good prognosis with a mortality rate of 0.3%, similar to that
2 reported by Morisco et al. (0.7%) and by George et al. (0.6%) in two independent studies.^{18,29}

3
4
5 The cumulative incidence of IGF/T2D in our population is 1.5%, the same reported by Giordanino
6 et al.³⁰ In their study, the authors stated that HCV eradication did not significantly reduce the risk of
7 IFG/T2D during 8 years FU and that the incidence of T2D was similar in LTRs compared to non-
8 responders at IFN or PegIFN plus RBV treatment.³⁰ In another study, Metha et al. demonstrated that
9 among 1084 non-diabetic subjects at baseline, HCV infection was associated with an elevated risk
10 of T2D development over 9 years FU.³¹

11
12
13
14
15
16
17
18 The incidence of cardiovascular events was 3-fold higher in CHC-LTRs who had HS at baseline
19 compared to those without HS, and this data is comparable to that reported in the Italian
20 population.³² The link between HCV infection and CAD is supported by the fact that HCV is able
21 to interfere with both glucose and lipid metabolism, leading to the development of IR, HS and T2D,
22 which are directly associated to atherosclerosis development.³³ Furthermore, HCV increases
23 cardiovascular risk by inducing a systemic inflammatory status and oxidative stress.³³ Specifically,
24 HCV infection promotes inflammation increasing pro-inflammatory cytokines levels such as
25 interleukin (IL)-6, tumor necrosis factor alpha (TNF- α), C-reactive protein (CRP) and fibrinogen
26 which in turn are associated with increased risk of CAD.³⁴⁻³⁵

27
28
29
30
31
32
33
34
35
36
37 According to previous data, we confirm that hepatic fibrosis is the main risk factor for the
38 development of hepatic complications.³⁶⁻³⁷ The incidence of HCC in our population was very low
39 (0.2%) and similar between CHC-LTRs who had HS at baseline and those who did not have HS.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
The association between HS and fibrosis in the setting of HCV infection is controversial: while in
the majority of the studies a robust association has been reported,³⁸⁻⁴⁰ some authors did not find any
relationship.⁴¹

Our study has some limitations. The first is the lack of a second liver biopsy making difficult the
longitudinal comparison of the degree of hepatic fibrosis and steatosis. Nevertheless, from an

1 ethical point of view, in the clinical setting, it would be difficult to perform a second liver biopsy
2
3 for histological reevaluation. The second limitation is the retrospective design of the study making
4
5 difficult to find clinical data from old medical records. Furthermore, during the last 30 years, all
6
7 consultations has been recorded in both a paper archive and a digital databank. However, the
8
9 potential heterogeneity arising from this, is limited by the fact that in our unit all authors followed
10
11 international guidelines. Finally, we are aware that the lack of data on alcohol consumption in our
12
13 cohort may represent another important limitation. However, all patients stopped drinking at the
14
15 time of HCV diagnosis and during antiviral treatment.
16
17

18 In conclusion, this study indicates that in a population of CHC-LTRs to IFN-based therapies, SVR
19
20 is associated with a good prognosis. Notwithstanding this, the presence of HS at baseline may
21
22 predispose to the development of cardiovascular events and T2D during follow-up emphasizing the
23
24 importance of an accurate counseling in order to prevent extra-hepatic complications.
25
26
27
28

29 References

- 30
31 1. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C
32 patients with sustained virological response to interferon monotherapy. *Gut* 2004;53:1504-8.
- 33
34 2. Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, et al. IL28B
35 polymorphism genotyping as predictor of rapid virologic response during interferon plus
36 ribavirin treatment in hepatitis C virus genotype 1 patients. *World J Gastroenterol*
37 2014;28:13146-52.
- 38
39 3. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical
40 outcomes after successful HCV therapy: a 5-years follow-up of 150 patients. *Hepatology*
41 2009;49:729-738.
- 42
43 4. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver
44 Diseases. Diagnosis, management, and treatment of hepatitis C. *Hepatology*. 2004;39:1147-
45 1171.
- 46
47 5. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical
48 Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines
49
50
51
52
53
54
55

- 1 for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert
2 Opinion Meeting. *Dig Liver Dis.* 2010;42:81-91.
3
4 6. Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of
5 chronic hepatitis C after successful interferon therapy. *J Med Virol* 2004;74:406-413.
6
7 7. Hung CH, Lee CM, Lu SN, et al. Long-term effects of interferon alpha-2b plus ribavirin
8 therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related
9 cirrhosis. *J Viral Hepat* 2006;13:409-414.
10
11 8. Caviglia GP, Rosso C, Fagoonee S, Saracco GM, Pellicano R. Liver fibrosis: the 2017 state
12 of art. *Panminerva Med* 2017;59:320-31.
13
14 9. Abenavoli L, Boccuto L, Masarone M, Pellicano R, Persico M. Adiponectin in hepatology.
15 *Minerva Biotech* 2018;30:29-35.
16
17 10. Bugianesi E, Salomone F, Negro F. The interaction of metabolic factors with HCV
18 infection: does it matter? *J Hepatol* 2012;56:S56-65.
19
20 11. Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, et al. Suppressor of cytokine
21 signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. *J Virol*
22 2010;84:6060-9.
23
24 12. Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype
25 3a increases SOCS-7 expression through PPAR-(gamma) in Huh-7 cells. *J Gen Virol*
26 2010;91:1678-86.
27
28 13. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis
29 accelerates the progression of liver damage of chronic hepatitis C patients and correlates
30 with specific HCV genotype and visceral obesity. *Hepatology* 2001;33:1358-1364.
31
32 14. Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies
33 on lipoproteins for its life cycle. *World J Gastroenterol* 2016;14:1953-65.
34
35 15. Jhaveri M, Procaccini N, Kowdley KV. Update on hepatitis C treatment: systematic review
36 of clinical trials. *Minerva Gastroenterol Dietol* 2017;63:62-73.
37
38 16. Ishak KG. Pathologic features of chronic hepatitis. *Am J Clin Pathol* 2000;113:40-55.
39
40 17. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Association of chronic
41 hepatitis C with metabolic and cardiac outcomes. *Aliment Pharmacol Ther* 2013;37:647-52.
42
43 18. Morisco F, granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained
44 virological response: a milestone in the treatment of chronic hepatitis C. *World J*
45 *Gastroenterol* 2013;19:2793-8.
46
47
48
49
50
51
52
53
54
55

- 1 19. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affect
2 chronic hepatitis C progression in a genotype specific way. *Gut* 2004;53:406-12.
- 3
- 4 20. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific
5 mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol*
6 2002;17:873-81.
- 7
- 8
- 9 21. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis
10 accelerates the progression of liver damage of chronic hepatitis C patients and correlates
11 with specific HCV genotype and visceral obesity. *Hepatology* 2001;33:1358-1364.
- 12
- 13 22. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to
14 chronic liver disease. *Hepatology* 2005;42:987-1000.
- 15
- 16 23. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C:
17 association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
18 *Gastroenterology* 2008;134:416-423.
- 19
- 20 24. Ihaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in
21 hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. *J*
22 *Infect Dis* 2008;197:283-291.
- 23
- 24 25. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to
25 hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to
26 antiviral therapy. *Hepatology* 2002;36:1266-1272.
- 27
- 28 26. Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C.
29 *Minerva Gastroenterol Dietol* 2006;52:125-34.
- 30
- 31 27. Negro, F. Mechanisms of hepatitis C virus-related insulin resistance. *Clin Res Hepatol*
32 2011;35:358-363.
- 33
- 34 28. Lerat H, Imache MR, Polyte J, Gaudin A, Mercey M, Donati F, et al. Hepatitis C virus
35 induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. *J Biol*
36 *Chem* 2017;292:12860-73.
- 37
- 38 29. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM.
39 Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-
40 years follow-up of 150 patients. *Hepatology* 2009;49:729-38.
- 41
- 42 30. Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, et al. Incidence of
43 type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C
44 infection by response to treatment: results of a cohort study. *Am J gastroenterol*
45 2008;103:2481-7.
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55

- 1 31. Metha SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C
2 virus infection and incident type 2 diabetes. *Hepatology* 2003;38:50-6.
- 3
- 4 32. <https://www.istat.it/it/>
- 5
- 6 33. Petta S. Hepatitis C virus and cardiovascular: a review. *J Adv Res* 2017;8:161-8.
- 7
- 8 34. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, et al.
9 Hepatic steatosis and insulin resistance are associated with serum imbalance of
10 adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. *Aliment Pharmacol*
11 *Ther* 2006;24:1349-57.
- 12
- 13 35. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, et al. Interplay between
14 oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. *J Hepatol*
15 2008;48:399-406.
- 16
- 17 36. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco GM, Thursz M, et al. Long-term
18 follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-
19 related complications. *J Viral Hepat* 2007;14:556-63.
- 20
- 21 37. Van der Meer AJ, Bart J, Feld JJ, Wedemeyer H, Dufour JP, Lammert F, et al. Association
22 between sustained virological response and all-cause mortality among patients with chronic
23 hepatitis C and advanced hepatic fibrosis. *JAMA* 2012;308:2584-93.
- 24
- 25 38. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on
26 progression of fibrosis in patients with mild hepatitis C. *Hepatology* 2005;41:82-7.
- 27
- 28 39. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship
29 between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of
30 individual patient data. *Gastroenterology* 2006;130:1636-42.
- 31
- 32 40. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis
33 in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. *J*
34 *Clin Gastroenterol* 2009;43:758-64.
- 35
- 36 41. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver
37 fibrosis is not associated with steatosis but with necroinflammation in French patients with
38 chronic hepatitis C. *Gut* 2003;52:1638-43.
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55

Tables**Table 1.** Baseline clinical, biochemical and histological characteristics of CHC infected patients in the whole cohort and according to the presence histological steatosis.

Variables	All (N=188)	CHC (N=106)	HS-CHC (N=82)	P value
Age (years)	46 ± 12	45 ± 12	48 ± 11	0.043
M/F, n	114/74 (61/39)	58/48 (55/45)	56/26 (68/32)	0.082
BMI (kg/m ²)	24.3 ± 3.2	23.7 ± 3.0	25.1 ± 3.4	0.007
HCV genotype, n (%)				0.019
1a/1b	111 (59.0)	67 (63.2)	44 (53.7)	
2a/2c	41 (21.8)	27 (25.5)	14 (17.1)	
3a	33 (17.6)	11 (10.4)	22 (26.8)	
4	3 (1.6)	1 (0.9)	2 (2.4)	
AST (U/L)	57 (55-67)	59 (52-72)	56 (55-67)	0.658
ALT (U/L)	82 (78-93)	85 (76-97)	82 (77-104)	0.605
gGT (U/L)	45 (37-52)	40 (34-45)	50 (34-67)	0.149
Hb (g/dL)	14.6 ± 1.4	14.5 ± 1.3	14.7 ± 1.5	0.551
Platelets (x10 ⁹)	211 (201-220)	210 (206-232)	203 (187-220)	0.176
Total cholesterol (mg/dL)	175 (168-182)	173 (160-179)	183 (168-193)	0.166
Triglycerides (mg/dL)	101 (90-110)	98 (88-112)	102 (89-116)	0.253
Glucose (mg/dL)	88 (84-91)	85 (83-88)	92 (88-95)	0.097
Log ₁₀ HCV-RNA	5.86 ± 0.69	5.82 ± 0.62	5.91 ± 0.78	0.456
Follow-up (years)	11 ± 4	12 ± 5	11 ± 4	0.412
Histology				
Fibrosis mstage, n (%)				0.585
F1	23 (12.2)	16 (15.1)	7 (8.5)	
F2	54 (28.7)	28 (26.4)	26 (31.7)	
F3	63 (33.5)	36 (34.1)	27 (32.9)	
F4	16 (8.5)	8 (7.5)	8 (9.8)	
F5	14 (7.4)	8 (7.5)	6 (7.3)	
F6	18 (9.6)	10 (9.4)	8 (9.8)	
Inflammation grading	4.8 ± 2.1	4.6 ± 1.9	5.1 ± 2.2	0.139

Data are reported as mean ± standard deviation or as median (95% confidence interval for the median). ALT, alanine aminotransferases; AST, aspartate aminotransferases; BMI, body mass index; CHC, chronic hepatitis

1 C; F, female; gGT, glutamyl-aminotransferases; Hb, hemoglobin; HS, hepatic steatosis; M, male; SD,
2
3 standard deviation.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

PEER REVIEW COPY
Minerva Medica

Table 2. Liver-related and cardio-metabolic-related mortality/morbidity according to the presence of hepatic steatosis.

Events (N) and cumulative incidence (%)	All (N=188)	No HS (N=106)	HS (N=82)	P
Mortality				
All causes	6 (0.3)	2 (0.2)	4 (0.5)	0.144
Liver-related	2 (0.1)	-	2 (0.2)	0.081
Cardiovascular-related	3 (0.2)	1 (0.09)	2 (0.2)	0.342
Other causes	1 (0.05)	1 (0.09)	-	0.527
Liver-related events				
Liver-related events	5 (0.3)	3 (0.3)	2 (0.2)	0.978
Cirrhosis and complications	2 (0.1)	1 (0.1)	1 (0.1)	0.423
HCC	3 (0.2)	2 (0.2)	1 (0.1)	0.848
Cardiovascular events				
CAD	14 (0.7)	4 (0.4)	10 (1.2)	0.011
Arterial hypertension	24 (1.3)	13 (1.2)	11 (1.3)	0.610
Metabolic-related outcomes				
Ow/Ob	22 (1.2)	10 (0.9)	12 (1.5)	0.073
IFG/T2D	28 (1.5)	9 (0.8)	19 (2.3)	0.005
Dyslipidemia	52 (2.8)	27 (2.5)	25 (3.0)	0.010

The cumulative incidence rate per 100 person-year was derived by the ratio of the number of events to the patient-years per 100. Group 1, long-term steatosis; group 2, incident steatosis; group 3, improved steatosis; group 4, no history of steatosis.

The p value has been derived from the Logrank test and is referred to the comparison of survival curves.

CAD, cardiovascular diseases; HCC, hepatocellular carcinoma; IFG, impaired fasting glucose; Ob, obese;

Ow, overweight; T2D, type 2 diabetes mellitus.

Table 3. Univariate and multivariable Cox regression analysis of viral and metabolic cofactors associated to the development of cardiovascular events during follow-up.

Variables	Univariate analysis		Multivariable analysis	
	OR (95% CI)	P value	OR (95% CI)	P value
Age	1.0 (0.9-1.1)	0.078	-	-
Sex (male)	2.0 (0.6-7.4)	0.281	-	-
BMI \geq 24.9 kg/m ²	1.7 (0.6-4.9)	0.838	-	-
HCV genotype 3a	0.4 (0.1-3.4)	0.430	-	-
HCV genotype 1a/b	0.9 (0.3-3.1)	0.999	-	-
IFG/T2D	7.7 (2.4-24.3)	<0.001	5.2 (1.3-20.7)	0.019
Dyslipidemia	3.5 (1.1-10.8)	0.028	-	-
Arterial hypertension	2.9 (0.6-13.0)	0.171	-	-
Hepatic steatosis	3.3 (1.0-10.7)	0.046	-	-

BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; IFG, impaired fasting glucose; OR, odd ratio; T2D, type 2 diabetes.

Table 4. Univariate and multivariable Cox regression analysis of viral and metabolic cofactors associated to the development of glucose intolerance or type 2 diabetes during follow-up.

Variables	Univariate analysis		Multivariable analysis	
	OR (95% CI)	P value	OR (95% CI)	P value
Age	1.1 (1.0-1.1)	0.001	1.1 (1.0-1.1)	0.008
Sex (male)	0.8 (0.4-1.7)	0.570	-	-
BMI \geq 24.9 kg/m ²	1.7 (0.8-3.6)	0.171	-	-
HCV genotype 3a	0.7 (0.2-2.3)	0.541	-	-
HCV genotype 1a/b	0.6 (0.3-1.3)	0.224	-	-
Dyslipidemia	3.7 (1.6-8.4)	0.002	-	-
Arterial hypertension	0.8 (0.2-3.6)	0.779	-	-
Hepatic steatosis	3.1 (1.4-6.9)	0.005	2.6 (1.1-6.2)	0.027

BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; IFG, impaired fasting glucose; OR, odd ratio; T2D, type 2 diabetes.

1 **Figures legend**

2
3 **Figure 1.** Flow-chart of the study.

4
5 HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; IFN, interferon; LTRs, long term responders; NR, non-
6
7 responders.


8
9
10
11 **Figure 2.** Kaplan-Meier survival curves showing the probability to develop cardiovascular events
12 according to the presence of impaired fasting glucose/type 2 diabetes (A), dyslipidemia (B) and
13
14 hepatic steatosis (C) at baseline.

15
16
17 Differences between the curves were determined by the Logrank test.

18
19
20 FU, Follow-up; IFG, impaired fasting glucose; T2D, type 2 diabetes.


21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

PEER REVIEW COPY
Minerva Medica



PEER REVIEW COPY
Minerva Medica

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Download supplementary material file: [Minerva Med-6108_1_V1_2019-04-16.doc](#)

PEER REVIEW COPY
Minerva Medica

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55